CURE’s ovarian cancer page is a go-to resource for oncology news and updates in the world of ovarian cancer Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in ovarian cancer.
September 29th 2020
Five-year follow-up data from the phase 3 SOLO-1 trial demonstrates a nearly five-year delay in disease progression with Lynparza compared with a delay of just over a year with placebo in women with newly diagnosed, advanced ovarian cancer harboring a BRCA gene mutation.
September 28th 2020
A weekly high dose of chemotherapy did not improve survival for patients with epithelial ovarian cancer, though the treatment regimen was effective and well-tolerated.
September 11th 2020
A proposed preventive surgery that would take out fallopian tubes before menopause but save ovary removal until afterwards was favored by most premenopausal previvors of ovarian cancer in a study.
September 11th 2020
The study results also showed that older age was significantly associated with lower cancer genetics knowledge, which, according to a post-doctoral research fellow at Dana-Farber Cancer Institute, is important because older adults may serve as a resource for family members who seek information about their family's health history.
September 10th 2020
Compared to physician’s choice of chemotherapy, the MEK inhibitor Mektovi failed to improve progression-free survival in patients with low-grade serous ovarian carcinomas. However, the study authors note Mektovi demonstrated promising results that support continued use of the treatment.
September 8th 2020
The National Ovarian Cancer Coalition to host its annual "Together in Teal®" No Boundaries National Broadcast Celebration During September awareness month on Saturday, Septemeber 26, 2020.
September 3rd 2020
Immediate treatment with Lynparza after standard surgery and chemotherapy should be considered for all patients with newly diagnosed stage 3 or 4 ovarian cancer that carries a BRCA gene mutation, even if residual disease remains, researchers have found.
August 28th 2020
Nearly half (48%) of the patients reported experiencing significant fatigue following their surgery. Thirty-nine percent of the patients still reported significant fatigue one year following their surgery.
August 27th 2020
Here is a list of the recent trial initiations that occurred within the cancer space in August.
August 18th 2020
While 75% of patients with gynecological cancers and COVID-19 will recover, new data from New York City shows specific risks for patients with cancer infected with COVID-19.
August 3rd 2020
A roundup of the latest news and updates for patients with ovarian cancer from CURE®.
July 14th 2020
Although the study failed to meet its goal of progression-free survival, overall survival data are currently not yet available, and follow-up will continue until the next planned analysis.
July 14th 2020
Ten percent of women who received a hysterectomy and salpingectomy, or removal of the fallopian tubes, during the study period had a family history of breast or ovarian cancer.
July 13th 2020
A recent data analysis found that most women diagnosed with ovarian cancer (92%) experienced abdominal and pelvic-related symptoms and visited a physician with this complaint anywhere from six to 70 months prior to diagnosis.
July 7th 2020
Dr. Jubilee Brown discussed the use of telemedicine and oral treatment options for patients with ovarian cancer, as well as offered advice to ease stress and anxiety throughout the COVID-19 pandemic.
June 15th 2020
The combination of mirvetuximab soravtansine and Avastin (bevacizumab) demonstrated encouraging overall response rates in patients with ovarian cancer, regardless of the disease’s previous responsiveness to platinum-based chemotherapy, according to data presented at the 2020 ASCO Virtual Scientific Program.
June 11th 2020
The presentation of the complete data from the NRG-GY004 trial comes just months after AstraZeneca and Merck announced in a press release that the combination failed to meet its primary endpoint of progression-free survival.
June 2nd 2020
Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for May 2020.
May 23rd 2020
One survivor makes the most of the time in the infusion chair, creating beaded jewelry and helping herself and others to heal.
May 21st 2020
In this episode of the “CURE Talks Cancer” podcast, we spoke with a cervical cancer survivor - who is currently living with ovarian cancer - about a cross-country journey she took last summer on a teal and white Harley Davidson motorcycle to raise ovarian cancer awareness.
May 21st 2020
The Food and Drug Administration recently approved the combination of Lynparza (olaparib) and Avastin (bevacizumab) for patients with advanced ovarian cancer that carries a specific mutation and has responded to previous treatment with platinum-based chemotherapy plus Avastin. Here’s what you need to know.
May 20th 2020
The Food and Drug Administration’s recent approval of Zejula is different from previous approvals as it is indicated for all patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, according to a gynecologic oncology expert.
May 14th 2020
Treatment with Lynparza in the maintenance setting extended overall survival by more than a year in women with platinum-sensitive relapsed ovarian cancer with BRCA1/2 mutations.
May 8th 2020
Lynparza and Avastin are now approved for patients with advanced ovarian cancer that carries a specific mutation and has responded to previous treatment with platinum-based chemotherapy plus Avastin.
April 29th 2020
The Food and Drug Administration has approved the use of Zejula as a frontline maintenance treatment for adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who responded to chemotherapy.
April 16th 2020
The COVID-19 pandemic has changed how people receive health care services. For Donna Wiegle, director of the Mill Pond Health Center in Maine, and cervical cancer survivor and patient with ovarian cancer, the pandemic hasn’t yet changed how her island’s health center provides residents with routine care.
April 14th 2020
A two-time survivor shares how taking action led her doctors to catch an aggressive second cancer.
April 13th 2020
After failing to meet its primary endpoint of progression-free survival, the JAVELIN Ovarian PARP 100 clinical trial was stopped.